JWH-133

JWH-133 is a drug that belongs to the cannabinoid family. It is a synthetic cannabinoid and a selective CB2 receptor agonist. JWH-133 has been used in scientific research to investigate the role of the CB2 receptor in the body's immune response, pain management, and inflammation.

Chemistry

JWH-133 is a synthetic cannabinoid, meaning it is not naturally occurring but is instead created in a laboratory. It is part of the JWH series of cannabinoids, which were developed by the chemist John W. Huffman.

Pharmacology

JWH-133 is a selective agonist for the CB2 receptor, meaning it binds to this receptor and activates it. The CB2 receptor is primarily found in the immune system, and its activation is associated with immune response and inflammation. JWH-133 has been shown to have anti-inflammatory effects in animal studies.

Research

Research on JWH-133 has primarily focused on its potential therapeutic uses. Studies have suggested that it may have potential in treating conditions such as chronic pain, multiple sclerosis, and arthritis. However, more research is needed to fully understand its effects and potential uses in medicine.

Legal status

The legal status of JWH-133 varies by country. In some countries, it is classified as a controlled substance, while in others it is legal for research purposes.

See also

• Cannabinoid receptor
• JWH-018
• JWH-073
• JWH-200

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia